Latest news with #Arcturus

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Globe and Mail

24-07-2025

Business
Globe and Mail

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Arcturus Therapeutics Holdings Inc. (the 'Company', 'Arcturus', Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2025 after the market close on Monday, August 11 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 11, 2025. Arcturus Therapeutics Second Quarter 2025 Earnings Conference Call Monday, August 11, 2025 @ 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS Webcast: Link About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat OTC deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit In addition, please connect with us on X (formerly Twitter) and LinkedIn.

Business Wire

24-07-2025

Business
Business Wire

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

‘Loud boom, woke me up': Another earthquake this week gets attention of Burlington residents

Hamilton Spectator

20-07-2025

General
Hamilton Spectator

‘Loud boom, woke me up': Another earthquake this week gets attention of Burlington residents

Burlington was hit with another earthquake mid-week and residents — at least the ones near where it hit — were talking about it on social media. It was small, as the ones in this area typically are — only 1.4 magnitude, according to Earthquakes Canada. But, like the last mini earthquake noticed by residents in Burlington in December ( read our story here ), it was felt by some residents, as this subsequent chat on a Burlington Reddit forum underscores. 'Did anybody else feel the ground shake or hear what sounded like a distant explosion around 12:30 a.m.? I heard something around New Street and Burloak area,' questioned Arcturus on a Burlington Reddit channel. And the responses to that question flowed in. 'Loud boom, woke me up, felt at Lakeshore Appleby,' posted Somasund4r. 'Similar at Lakeshore / Hampton Heath. I had headphones on but everyone else thought it was more serious than I had originally thought,' posted Loon-attack. 'Wife woke me up,' posted moderator1233. 'Yes!' Rapdeng12 responded: 'Just came on here to check because I heard the loud boom and felt a little shake. Felt very similar to the earthquake last (December), so I wondered if it was a small earthquake again.' 'We actually get earthquakes in Burlington more often than you would think, sometimes the lights flicker or the lamp swings a little … it's not a ghost, even though that's what I told my sister when we were little, lol,' posted Complex-Series7727. 'You could hear it and feel it at New and Appleby. I wanna know what it was, it was so scary,' posted Odd-Television-9724. 'Me too!!! Came on to check also. Our house shook! Never heard anything like that! Walkers Line and New area here.' posted SansOP_2019. 'Felt it quite strongly at Appleby and Lakeshore, woke everyone in my house up,' posted Clear-Medicine-9770. 'Yes! Pinedale and Appleby,' posted OkAcanthaceae2216. 'Yup. Heard here too. Fairview and Walkers. Someone please provide updates if they find out what happened,' posted Significant_Cod_9257. 'If there was a quake, I'm pretty sure there would be something in the news about it today but I can't find anything confirming a quake,' posted MalibuMabel. 'The one that happened last summer, it took the news over a week to post about it,' posted ryanelmo. The above Reddit thread also mentions a website run by Canadian government agency called Earthquakes Canada which, as the name suggests, posts all of the earthquakes it records across the country (as well as those that might affect the country), along with other resources. The home page features a map with all the earthquakes in Canada during the last 30 days. The quakes — some big (almost always along the west coast) and some small (like the ones the Burlington area gets) — are too numerous to report on all of them. You can narrow it down to our region by zooming in on the map or clicking on southern Ontario region . The Burlington earthquake is coloured in red, as it is the most recent (as of July 19). If you click on it, it tells you the magnitude was 1.4, which is really small. It also gives you the option to generate it in list form. It may have been a small earthquake but as the Reddit post amply attests, it did receive this designation: 'Felt.' As did the December Burlington earthquake, noted above. We asked Nick Ackerley, a seismologist with Natural Resources Canada's Canadian Hazard Information Service. In an email, he pointed to Earthquakes Canada's online research database , which shows 'this event (the July 19 Burlington earthquake) is part of a cluster of very low-magnitude seismicity.' The chart shows the July and December Burlington earthquakes were preceded by four earthquakes on the same day and relatively same area in Milton on May 11, all ranging between 1.5 and 1.9 magnitude. Prior to this, the last one for this area listed by Earthquakes Canada was back in 2011 on Nov. 28 at 2.3 magnitude and previous to that on July 17 in 2009 at 1.7 magnitude. 'For perspective,' explained Ackerley, 'we don't expect damage until magnitude 5, although smaller events can be widely felt. 'And, crucially, one unit of magnitude is equivalent to a factor of 10 in the amplitude of the resulting ground shaking. So the (July 16) event in Burlington produced shaking that was more than 1,000 times smaller than that expected to cause damage.' The fact the Burlington events were felt despite being relatively small, he attributed to two factors. 'I think we can say that this event was only felt because it occurred in a populated area and was shallow,' he stated. Most earthquakes in Canada, he said, 'occur near the middle of the crust, which is on average 36-kilometres thick in eastern Canada.' The Burlington 1.4 magnitude event at 18-km depth, he said, would unlikely to be felt. 'We don't have sensors close enough to enable us to accurately estimate the depth for these events near Burlington, but for some events in this sequence we observed a type of seismic wave that is only visible when the depth is less than 5 km. 'The fact that it was felt can be seen as evidence that it was shallow.' As for what caused it, he said, 'We don't know much about what caused these earthquakes near Burlington, except that postglacial rebound is likely one of the main contributors to the local stress field.' Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .

A tale of two planets in the evening glow

Otago Daily Times

11-07-2025

Science
Otago Daily Times

A tale of two planets in the evening glow

Image: Ian Griffin There's something quietly marvellous about stepping outside just after sunset in midwinter. The chores of the day are mostly done, the fire crackling inside, and the sky — well, the sky is just getting started. This week, the evening twilight holds a planetary treat for those with a bit of patience and a clear view to the northwest. Low in the fading glow of the sun, the elusive planet Mercury puts in a rare appearance. If you catch it — just above the horizon as the sky darkens — you're seeing a world just over 105 million kilometres away. Through a telescope, Mercury appears as a delicate crescent, only about 25% illuminated, and is very small. It's in the constellation Cancer, a dim patch of sky that doesn't offer much in the way of bright stars but does cradle the lovely Beehive Cluster — though you'll need binoculars and dark skies to find it. A bit higher in the sky, not far behind the departing sun, Mars lingers in the western sky. It's a rusty speck now, not as bright as it can be during closer approaches, but still worth seeking out. At more than 300 million kilometres away, Mars is far beyond Mercury's neighbourhood, and tonight it lies in Leo. That constellation is ruled by Regulus, a hot blue-white star that marks the heart of the lion. Regulus is a respectable 79 light years away, and if you're feeling poetic, you could imagine it as the lion's beating heart, pulsing softly in the velvet dark. Stand there a moment longer. Let your eyes adjust. Above Leo lies Virgo, and further still, the mighty Arcturus in Bootes glows amber and steady. And if you glance low in the west, you'll just catch Sirius — still hanging on, the dog star defying winter's chill. If you stay out too long, your nose will feel the bite of frost, but your soul might just feel warmer. Midwinter skies ask little of us — just time and perhaps a decent jacket — and in return, they offer the vast, quiet company of planets and stars. Worth it, I'd say.

Business Wire

30-06-2025

Business
Business Wire

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the 'Company', 'Arcturus', Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announces positive Phase 2 interim results in people with OTC deficiency treated with ARCT-810, an mRNA therapeutic candidate designed to replace the OTC enzyme and restore urea cycle activity preventing hyperammonemia crises. 'We are very pleased with these new ARCT-810 clinical results, where we have achieved strong biological effects in both Phase 2 studies, including significant and consistent reduction and normalization of abnormally elevated glutamine, an important biomarker to monitor urea cycle function,' said Dr. Juergen Froehlich, Chief Medical Officer of Arcturus. 'Furthermore, in our ongoing U.S. Phase 2 study, we are excited to report the first significant relative ureagenesis function (RUF) improvements using a new and optimized 15 N-ureagenesis assay. Along with the observation of stable ammonia levels in all patients during treatment, these data add a level of robustness to this new interim dataset. I am also very pleased to see that our LUNAR® delivery technology continues to be generally safe and well tolerated. The combined biomarker data is unprecedented for an mRNA rare disease therapeutic and, importantly, provides a potentially accelerated path forward to a multi-biomarker driven pivotal study.' 'It is extremely rewarding to see the first mRNA therapeutic produce such solid clinical results in an area of important unmet medical need,' said Dr. Marshall Summar, CEO of Uncommon Cures. 'This is a very positive step for the OTC deficient community as there are currently limited options for symptomatic patients suffering from this devastating disease.' Multiple dosing data are available from two Phase 2 studies; a completed placebo-controlled study in Europe that randomized six participants to ARCT-810 doses and an open-label multiple ascending dose study with interim data from the initial three completed participants. The ongoing U.S. Phase 2 open-label study uses a modified and improved 15 N-ureagenesis assay (Allegri et al., 2025). The assay measures relative ureagenesis function (RUF) against a normal range established from healthy controls (N = 29). The assay is not impacted by ammonia scavengers, has low intraindividual variability, and can distinguish between symptomatic and asymptomatic OTC deficient patients. Linear Mixed-Effects Model (LMM) was applied as an exploratory analysis to the Phase 2 glutamine and ureagenesis data. LMM is suitable for small-N analyses, i.e. rare disease trial datasets. ARCT-810 treatment significantly reduces glutamine levels In the combined analysis of both Phase 2 studies, significantly (p-value = 0.0055; LMM) decreased glutamine levels were observed following multiple ARCT-810 administrations to patients who remained on their standard of care therapy. These results provide statistical evidence that glutamine levels decrease over time in both Phase 2 studies, suggesting a robust effect across the patient cohorts. In the Phase 2 randomized European study, glutamine levels in patients who received multiple doses of ARCT-810 significantly (p-value = 0.016; LMM) decreased during the dosing period. In the Phase 2 open-label U.S. study, all three participants had a sustained and significant (p-value = 0.004; LMM) decrease in glutamine from baseline reaching normal levels after the first three doses. These results provide strong evidence that glutamine levels decreased in both Phase 2 studies, with a steeper decline in the U.S. Phase 2 study, likely attributed to the two participants with more severe disease. After treatment completion, glutamine levels returned to baseline over a period of several weeks. ARCT-810 treatment significantly increases 15 N-ureagenesis In the first three participants in the ongoing Phase 2 open-label study, RUF statistically (p-value = 0.026, LMM) increased at all post treatment evaluations from a baseline of 29.0% (SD; 9.1%) to 43.7% (SD; 21.7%) at 28 days post-fifth dose. These results suggest a progressive increase of functional OTC enzyme in the liver with continued administrations. Two of the three participants achieved RUF > 50% indicating a clinically meaningful improvement in urea cycle flux. These encouraging 15 N-Ureagenesis data provide additional support and confidence in the favorable glutamine results. Ammonia remained stable and within normal range Further supporting the favorable glutamine and ureagenesis data, patients receiving ARCT-810, in both Phase 2 studies, maintained ammonia levels within the normal range following at least two doses and remained stable for approximately 28 days after completion of dosing. Two participants in the European Phase 2 randomized study (one receiving placebo, one receiving ARCT-810) reported a hyperammonemia event (ammonia ≥ 100 μmol/L). One participant had normal ammonia levels that remained stable during ARCT-810 treatment; four weeks after the last dose, this participant received an oral corticosteroid to treat an asymptomatic transaminase elevation (a laboratory SAE that did not meet Hy's law criteria). Subsequently, transaminase levels returned to normal range, and the temporary increase of ammonia was considered related to corticosteroid treatment. ARCT-810 continues to be safe and well tolerated ARCT-810 was generally safe and well tolerated in single dose Phase 1/1b and multi-dose Phase 2 studies, comprising 40 participants to date, including 20 OTC deficient participants. The early studies enabled the Company to improve the tolerability of the infusion regimen without using corticosteroid pre-treatment. To date, no serious IRRs have been observed using the improved 3-hour IV regimen (N = 8; up to 6 infusions) in the Phase 2 protocols. Virtual KOL Event: Monday, June 30, 2025 @12:00 p.m. ET About Ornithine Transcarbamylase Deficiency Ornithine transcarbamylase (OTC) deficiency is the most common urea cycle disorder. Urea cycle disorders are a group of inherited metabolic disorders of the liver that make it difficult for affected patients to remove toxic waste products as proteins are digested. OTC deficiency caused by mutations in the X-linked OTC gene, leads to a non-functional or deficient OTC enzyme and usually affects males more severely. OTC is a critical liver enzyme which catalyzes a metabolic process that converts toxic ammonia to urea that is excreted by the kidney. This conversion does not occur properly in patients with OTC deficiency and, aside from the risk of high ammonia levels, leads to increased blood concentrations of glutamine with low to normal levels of citrulline and increases in urine orotic acid. High blood ammonia levels in OTC deficiency may cause health crises with seizures, progressive neurocognitive impairment, coma, and death. Severe cases of OTC deficiency usually present early in life, but patients with less severe symptoms may be diagnosed as adolescents and adults. There is currently no cure for OTC deficiency, apart from liver transplant. However, liver transplantation comes with significant risks of surgical and postsurgical complications such as organ rejection, and recipients must take immunosuppressant drugs for the rest of their lives. The current standard of care for OTC deficiency patients is a well-controlled, but challenging to maintain, low-protein diet, substitution of essential amino acids and treatment with nitrogen scavenging medications that keeps the ammonia from rising to acutely toxic levels but may not prevent chronic neurotoxic effects. These treatments do not address the underlying cause of disease. In Europe and the U.S., approximately 10,000 people have OTC deficiency. About ARCT-810 ARCT-810 is an intravenously administered investigational mRNA therapeutic designed to express normal functional OTC enzyme in the liver of individuals with OTC deficiency. ARCT-810 has received Orphan Medicinal Product Designation and an approved pediatric investigation plan (PIP) from the European Medicines Agency (EMA), and Orphan Drug Designation, Fast Track Designation along with Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for the treatment of OTC deficiency. OTC is a key enzyme in the urea cycle which converts toxic ammonia into urea. Elevated ammonia can lead to metabolic crises with progressive and irreversible neurocognitive damage. A safe and effective mRNA therapeutic may restore normal functional OTC enzyme in the liver which could improve urea cycle activity, reduce abnormally elevated glutamine, maintain normal ammonia levels and potentially eliminate the risk of future metabolic crises. ARCT-810 is based on Arcturus' mRNA design construct and proprietary manufacturing process. ARCT-810 also utilizes Arcturus' extensive and propriety lipid library and employs the Company's LUNAR® delivery platform to deliver OTC mRNA to hepatocytes. About Glutamine as a Biomarker Glutamine is used as an important biomarker by clinicians to monitor urea cycle function in OTC deficient patients. Glutamine reflects the body's nitrogen buffering capacity. In urea cycle disorders, excess nitrogen is initially incorporated into glutamine, allowing glutamine to rise steadily as a compensatory mechanism before ammonia levels begin to spike. This role makes glutamine a more stable and predictive biomarker in patients who are not experiencing hyperammonemia. Glutamine assessments have significantly lower intra-subject variability than ammonia (15% vs. 56%), making it more reliable for monitoring metabolic control in stable conditions (Lichter-Konecki et al., 2016). About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat OTC deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit In addition, please connect with us on X (formally Twitter) and LinkedIn. Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of success of the Company's pipeline (including ARCT-810), the likelihood that clinical results will be predictive of future clinical results or of potential therapeutic benefit, likelihood of continuation of the OTC program, likelihood of further enrollment in the ongoing ARCT-810 Phase 2 study, the likelihood of a path toward and initiation of a multi-biomarker driven pivotal study, the likelihood that continued ARCT-810 administrations will result in a progressive increase of functional OTC enzyme, the likelihood of any regulatory agency recognizing any biomarker in determinations of regulatory approval including glutamine levels or 15N assay results, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading "Risk Factors" in Arcturus' most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the Securities and Exchange Commission (the 'SEC'), which are available on the SEC's website at Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Latest news with #Arcturus

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

‘Loud boom, woke me up': Another earthquake this week gets attention of Burlington residents

A tale of two planets in the evening glow

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Get Started Now: Download the App